Alkermes: Q4 Earnings Snapshot [Yahoo! Finance]
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Yahoo! Finance
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported fourth-quarter earnings of $49.3 million. On a per-share basis, the Dublin-based company said it had profit of 29 cents. Earnings, adjusted for stock option expense and costs related to mergers and acquisitions, came to 46 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 43 cents per share. The drugmaker posted revenue of $384.5 million in the period, also beating Street forecasts. Seven analysts surveyed by Zacks expected $380 million. For the year, the company reported profit of $241.7 million, or $1.43 per share. Revenue was reported as $1.48 billion. Alkermes shares have risen 19% since the beginning of the year. The stock has dropped 6% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes to Report First Quarter Financial Results on May 5, 2026Business Wire
- Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual MeetingBusiness Wire
- Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical PsychiatryBusiness Wire
- Alkermes (ALKS) had its price target raised by Bank of America Corporation from $34.00 to $36.00. They now have a "neutral" rating on the stock.MarketBeat
- Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2Business Wire
ALKS
Earnings
- 2/25/26 - Miss
ALKS
Sec Filings
- 4/13/26 - Form 4
- 4/6/26 - Form 4
- 4/6/26 - Form ARS
- ALKS's page on the SEC website